Hillerstrom Hampus, Das Amit, Janicki Matthew P, Rozas Natalia S, Santoro Stephanie L
LuMind IDSC Foundation, Woburn, Massachusetts, USA.
University of Illinois Chicago, Chicago, Illinois, USA.
Alzheimers Dement. 2025 Sep;21(9):e70356. doi: 10.1002/alz.70356.
Diagnosing and staging Down syndrome-associated Alzheimer's disease (DS-AD) is hindered by the lack of standardized criteria, complicating clinical decision making, trial participation, and access to advanced therapies. This study aimed to explore perceptions of these issues.
An international survey of 42 clinicians and researchers specializing in DS-AD gathered perspectives on instruments, symptomatic staging, clinical practices, and research priorities.
Respondents noted that key domains of impairment in mild cognitive impairment in Down syndrome and DS-AD dementia included memory, executive functioning, personality, social behavior, attention, mood, and language. Among the 10 assessment tools evaluated, informant-based interviews were noted as critical for individuals with severe intellectual disability (ID), while direct assessments were noted as useful for those with mild to moderate ID. Common diagnostic confounders like hypothyroidism and sleep disorders were identified.
Behavioral assessments provide a valuable function; however, future efforts should integrate behavioral assessments with biomarkers and develop standardized staging frameworks to improve diagnostic reliability, care planning, and treatment strategies for DS-AD.
Personality, social behavior, language, mood/affect, memory, executive functioning, and attention are recognized as key domains of impairment in both mild cognitive impairment in Down syndrome (MCI-DS) and Down syndrome-associated Alzheimer's disease (DS-AD). Ten prominent informant and direct assessment tools were noted as appropriate for individuals with DS and mild to moderate intellectual disability (ID) for identifying both MCI-DS and DS-AD; however, for individuals with severe/profound ID, there was less assurance of applicability. Harmonizing recommended tools in a standardized list was identified as a strategy to promote consistency across clinical and research contexts.
由于缺乏标准化标准,唐氏综合征相关阿尔茨海默病(DS-AD)的诊断和分期受到阻碍,这使得临床决策、试验参与以及获得先进治疗变得复杂。本研究旨在探讨对这些问题的看法。
对42名专门研究DS-AD的临床医生和研究人员进行了一项国际调查,收集了关于工具、症状分期、临床实践和研究重点的观点。
受访者指出,唐氏综合征和DS-AD痴呆症中轻度认知障碍的关键损害领域包括记忆、执行功能、人格、社会行为、注意力、情绪和语言。在评估的10种评估工具中,基于 informant 的访谈被认为对重度智力残疾(ID)个体至关重要,而直接评估对轻度至中度ID个体有用。识别出了常见的诊断混淆因素,如甲状腺功能减退和睡眠障碍。
行为评估具有重要作用;然而,未来的努力应将行为评估与生物标志物相结合,并制定标准化的分期框架,以提高DS-AD的诊断可靠性、护理计划和治疗策略。
人格、社会行为、语言、情绪/情感、记忆、执行功能和注意力被认为是唐氏综合征轻度认知障碍(MCI-DS)和唐氏综合征相关阿尔茨海默病(DS-AD)的关键损害领域。10种著名的 informant 和直接评估工具被认为适用于患有DS和轻度至中度智力残疾(ID)的个体,以识别MCI-DS和DS-AD;然而,对于重度/极重度ID个体,其适用性的保证较少。将推荐工具统一列入标准化列表被确定为一种促进临床和研究环境一致性的策略。